Adherex Technologies (FENC) Receiving Somewhat Favorable Media Coverage, Study Shows
News coverage about Adherex Technologies (NASDAQ:FENC) has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adherex Technologies earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.17 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
About Adherex Technologies
Fennec Pharmaceuticals Inc, formerly Adherex Technologies Inc, is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Receive News & Ratings for Adherex Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.